Covid-19 cases are rising once again across several parts of the world, driven by the spread of the JN.1 variant – a new sub-lineage of Omicron known for its high transmissibility. While symptoms remain mostly mild, the latest spike has prompted health authorities in multiple countries to issue fresh public health advisories.
Cases are rising across Asia
Singapore has seen a sharp increase in cases, with 14,200 infections reported in the week ending 3 May, up from 11,100 the previous week. Hospital admissions also rose to an average of 133 per day, though the number of patients requiring intensive care fell slightly from three to two daily.
Hong Kong’s Centre for Health Protection described current virus activity as “quite high”, with the city recording its highest rate of respiratory samples testing positive in over a year. Authorities are monitoring the situation closely.
In Thailand, the latest surge is mostly affecting people aged 30 to 39, with health experts warning of more cases in the coming weeks. China, too, is experiencing a resurgence, although official figures remain limited.
India reports a modest increase
India has also recorded a slight uptick in Covid-19 cases. As of 19 May, the country had 257 active infections, with Kerala reporting the highest number (69), followed by Maharashtra (44) and Tamil Nadu (34). According to experts, most cases remain mild and do not require hospitalisation.
Health officials say the rise is partly due to the spread of the JN.1 variant, a drop in population-level immunity, and seasonal factors affecting people’s health. The increase in international travel is also believed to be contributing to the current wave.
What is the JN.1 variant?
The JN.1 variant has been labelled a “variant of interest” by global health bodies because of how quickly it spreads. Its symptoms include fever, sore throat, fatigue and mild respiratory issues. However, the severity of illness appears to remain low, particularly among those who have been vaccinated.
The variant has not been linked to increased hospital admissions or deaths, but public health authorities continue to urge caution.
Global health response
Authorities in affected countries are encouraging people to wear masks in crowded spaces, practise good hand hygiene, and stay home if they experience symptoms. While lockdowns and strict restrictions are not currently being considered, local measures could be introduced if hospital pressures increase.
In response to the broader pandemic preparedness challenge, the World Health Organisation recently adopted a historic Pandemic Agreement. The new framework aims to improve global cooperation and ensure a more equitable response to future pandemics, particularly in low- and middle-income countries.
As the world continues to navigate waves of Covid-19, experts are reminding the public not to become complacent. With new variants likely to emerge, maintaining basic precautions remains crucial in preventing further spread.
The presence of West Nile virus has been detected in mosquitoes in the UK, health officials said. The UK Health Security Agency (UKHSA) has stated that the general public faces a “very low” risk from the virus, although it can cause serious illness in rare cases.
Authorities said there is currently no evidence of further spread of the virus among mosquito populations.
West Nile virus is transmitted through mosquito bites. The virus, spread by bird-biting mosquitoes, has become increasingly common in various parts of the world, including mainland Europe.
Mosquitoes and the diseases they carry are influenced by environmental factors such as climate change, which is pushing such risks further north. Aedes vexans mosquitoes, which are native to Britain, are among the species migrating along with vector-borne diseases as temperatures rise.
Only seven cases of West Nile virus have been reported in the UK since 2000, all linked to travel abroad. No cases have been acquired within the UK.
The virus regularly causes outbreaks in regions including parts of Africa, Asia, South America and Europe — a trend that has grown over time.
A 2023 research programme conducted by UKHSA and the Animal and Plant Health Agency (APHA) identified the virus in mosquitoes collected from ponds near Retford, Nottinghamshire.
“While this is the first detection of West Nile virus in mosquitoes in the UK, it is not unexpected as the virus is already widespread in Europe,” said Dr Meera Chand, Deputy Director for Travel Health and Infections at UKHSA.
Dr Arran Folly, who led the research programme, said the finding reflects “a wider changing landscape, where, in the wake of climate change, mosquito-borne diseases are expanding to new areas”.
West Nile virus-carrying mosquitoes typically breed in standing water. Health experts recommend using insect repellents and bed nets, and eliminating standing water sources, to help prevent transmission.
The virus often causes mild or no symptoms, making it difficult to detect. Common symptoms include headaches, high fever and skin rashes. In severe cases, the infection can be fatal. Last year, protests were held in Seville, Spain, after five people died from the virus.
England is set to become the first country in the world to introduce a national gonorrhoea vaccination programme, in a move hailed by health officials as a “landmark moment for sexual health”. The rollout will begin on 1 August 2025 and will use an existing meningitis B vaccine, known as 4CMenB, to help combat soaring cases of gonorrhoea and growing concerns over antibiotic resistance.
The sexually transmitted infection (STI) reached record levels in England in 2023, with more than 85,000 cases reported — the highest number since records began in 1918. Health experts have warned that strains of the bacteria responsible for gonorrhoea, neisseria gonorrhoeae, are becoming increasingly resistant to current treatments.
The 4CMenB vaccine is currently used in the NHS childhood immunisation programme to protect against meningococcal group B disease, which can lead to serious conditions such as meningitis and sepsis. It is routinely administered to babies at eight weeks, 16 weeks, and one year of age. The vaccine contains proteins from neisseria meningitidis, a bacterium closely related to the gonorrhoea-causing strain, and has shown moderate effectiveness against gonorrhoea in clinical studies.
Research conducted by the Joint Committee on Vaccination and Immunisation (JCVI) estimates that the 4CMenB jab could provide between 32.7% and 42% protection against gonorrhoea. While it is not expected to completely prevent infection, experts say it significantly reduces the risk and offers vital protection, particularly for groups most at risk.
Dr Amanda Doyle, national director for primary care and community services at NHS England, said: “The launch of a world-first routine vaccination for gonorrhoea is a huge step forward for sexual health. It will be crucial in protecting individuals, helping to prevent the spread of infection, and reducing the rising rates of antibiotic-resistant strains of the bacteria.”
The vaccine will be offered through local authority-commissioned sexual health services, with eligible individuals identified and contacted in the coming weeks. At their appointment, patients will also be offered vaccinations for mpox (previously known as monkeypox), human papillomavirus (HPV), and hepatitis A and B.
Computer illustration of neisseria gonorrhoeaeAlamy
Gonorrhoea is currently the second most common bacterial STI in the UK. Symptoms may include green or yellow discharge from the genitals, pain while urinating, and rectal discomfort. Women may also experience lower abdominal pain or bleeding between periods. However, many people with the infection do not display any symptoms, increasing the risk of undetected transmission.
The new programme is being introduced amid warnings over rising resistance to ceftriaxone, the antibiotic most commonly used to treat gonorrhoea. In some cases, the bacteria have developed the ability to survive and multiply even after exposure to the drug. There is also growing concern about the emergence of extensively drug-resistant (XDR) strains — those which do not respond to ceftriaxone or second-line treatments.
According to the UK Health Security Agency (UKHSA), 17 cases of ceftriaxone-resistant gonorrhoea were recorded between January 2024 and March 2025, alongside nine XDR cases. This marks an increase from the five XDR cases reported between 2022 and 2023.
Dr Sema Mandal, consultant epidemiologist and deputy director at UKHSA, welcomed the vaccine rollout. “Not only will this rollout provide much-needed protection to those that need it most, but it will make the UK the first country in the world to offer this protection and a world leader in protecting people against gonorrhoea,” she said.
Health minister Ashley Dalton also urged eligible individuals to take up the offer of vaccination. “By targeting those most at risk, we can reduce transmission rates from this unpleasant disease that is becoming harder to treat and prevent thousands of cases over the next few years,” she said. “Getting vaccinated is not only about keeping yourself safe but also about helping tackle the growing threat of antibiotic resistance.”
The JCVI has previously highlighted that, unlike other infections, previous episodes of gonorrhoea offer little to no immunity against reinfection, making vaccination an important preventative step.
Richard Angell, chief executive of the sexual health charity Terrence Higgins Trust, called the jab a “gamechanger”, estimating that it could reduce new gonorrhoea cases by as much as 40%. He added, “This is a significant step forward in the fight against STIs and antimicrobial resistance. We encourage everyone eligible to come forward and get protected.”
NHS England is currently coordinating with local health teams to prepare for the rollout and ensure the new programme is fully operational from the start of August.
Keep ReadingShow less
Her journey reflects the challenges many international healthcare workers face
A nurse from Kerala who has worked to support fellow Malayali professionals in the UK has been invited to attend King Charles III’s garden party at Buckingham Palace in recognition of her contributions to the NHS and international nursing community.
Prabin Baby, 45, who currently works as a patient experience nurse in Hertfordshire, received the invitation in acknowledgement of her efforts to help internationally trained nurses, particularly from Kerala, integrate into the British healthcare system.
Originally from Tiruvalla, Kerala, Prabin moved to the UK in 2020 at the height of the COVID-19 pandemic. Despite her experience in Malaysia and India, including roles in clinical care and nursing education, she initially struggled to adapt to the NHS system. This personal challenge motivated her to assist others facing similar difficulties.
“When I arrived in the UK, I felt uncomfortable, despite having clinical experience and the required OET qualification,” Prabin said. “Internationally trained nurses face barriers in understanding the system. They need support, both professionally and culturally, to settle in. I believe someone has to step up and help.”
She joined Lister Hospital in Stevenage as a registered nurse before being promoted to educational and corporate roles within the East and North Hertfordshire NHS Trust. Through her work, she has supported the welfare and development of Malayali nurses, helping them to understand the NHS structure, workplace culture, and career development pathways.
Her professional growth was further supported by a fellowship with the Florence Nightingale Foundation Academy, which provided her with opportunities to develop her leadership skills and expand her work in supporting internationally educated staff. The NHS also funded her professional nurse advocate course, enhancing her ability to guide others in similar roles.
“I have always believed in collaboration with leadership to build an inclusive and supportive environment,” Prabin said. “Our trust is diverse and inclusive, and although there are many native English staff, I was honoured to be selected to attend the garden party.”
Speaking about the event at Buckingham Palace, Prabin said she felt proud and humbled as an Indian nurse. “There were times when I stood outside the palace and wondered what it was like inside. To have the opportunity to enter and meet the royals and others who have contributed to public service was a memorable experience.”
She credited her family—her daughter, parents and sister—for their continuous support. “They are my backbone and have always encouraged me in my work.”
Prabin also highlighted the broader professional opportunities available to nurses in the UK. “If we are interested and willing to learn, there is much scope to specialise and progress here. The recognition and appreciation we receive are often greater than in India or other developed countries.”
Her journey reflects the challenges many international healthcare workers face and the importance of mentorship, institutional support and inclusive leadership within the NHS.
Keep ReadingShow less
The initiative will empower more women to speak openly about their health
A new community-led initiative has been launched in the UK to provide culturally sensitive support for South Asian women navigating midlife and menopause.
The Sattva Collective, founded by certified Midlife and Menopause Coach Kiran Singh, officially launched on 14 May 2025 as a registered Community Interest Company (CIC). It is the first initiative in the UK focused specifically on the experiences of South Asian women during what Singh describes as a “deeply personal and often stigmatised” phase of life.
“South Asian women are navigating physical, emotional, and identity shifts in silence – often without the language, space, or support to talk about it,” Singh said. “The Sattva Collective is here to change that. We are reclaiming midlife as a powerful, transformative time – and doing it together.”
The name 'Sattva' is drawn from Sanskrit, referring to clarity, balance, and inner peace – values reflected in the collective’s approach.
The organisation will offer a range of services throughout the year, including:
Monthly community meet-ups in local cafés
Educational workshops on hormone health, mental well-being, and cultural stigma
An annual flagship Midlife Summit launching in January 2026
Public awareness campaigns and digital resources
One-to-one and group coaching sessions
Singh, who is of Indian heritage, aims to address the gaps in both mainstream and cultural conversations around menopause. According to her, many South Asian women face barriers to accessing support due to stigma, lack of awareness, and limited representation in public discourse.
The Sattva Collective is now preparing to roll out its 2025 programme and is actively seeking funding, sponsorship, and community partners to expand its reach and resources.
Describing midlife as “not a crisis, but a calling,” Singh hopes the initiative will empower more women to speak openly about their health and experiences, while building a supportive community.
Further details about upcoming events and resources will be made available through the collective’s official channels in the coming weeks.
Keep ReadingShow less
This may influence future decisions on treatment options for obesity patients
Eli Lilly announced on Sunday that its weight-loss drug, Zepbound, outperformed Novo Nordisk's Wegovy in a head-to-head trial, showing superior results across five weight-loss targets, including waist circumference reduction.
This trial, the first of its kind comparing the two widely used obesity medications, offers Eli Lilly a competitive advantage as it aims to secure broader insurance coverage in the rapidly growing obesity drug market, which is projected to exceed $150 billion annually by the next decade.
The results revealed that Zepbound helped nearly 25% more participants achieve a weight loss of over 15% compared to Wegovy. In addition, Zepbound demonstrated a more significant reduction in waist circumference, with an average decrease of 18.4 cm. In comparison, Wegovy participants saw an average reduction of 13 cm.
Novo Nordisk, in a statement sent via email on Monday, pointed out that the weight loss achieved by Wegovy in this trial was lower than what was observed in a 2021 trial with a similar dose. However, the company emphasised that Wegovy is the only GLP-1 agonist medicine approved to prevent major cardiovascular events, such as heart attacks, a critical benefit for patients with obesity. Novo also mentioned that a trial with a higher dose of semaglutide, Wegovy's active ingredient, conducted earlier this year, showed greater weight-loss results.
Lilly had previously reported in December that its obesity drug had already surpassed Wegovy, with patients treated with Zepbound losing 47% more weight than those who received Wegovy. These findings were also shared in a press release and presented at the European Congress on Obesity.
The timing of the trial results coincides with a recent decision by CVS Health to exclude Zepbound from some of its reimbursement lists, preferring Wegovy instead. This move highlights the ongoing competition between the two pharmaceutical giants in the obesity treatment space.
Zepbound mimics two gut hormones to support weight loss, while Wegovy relies on a single mode of action. In separate trials, Lilly's Zepbound helped patients lose more than 22% of their body weight after 72 weeks, while Wegovy led to a 15% reduction in weight after 68 weeks.
The growing competition in the weight-loss drug market is also impacted by another Eli Lilly medication, Mounjaro, which has shown positive results for diabetes and weight loss. With these advancements, Eli Lilly is positioning itself as a major player in the obesity treatment landscape.
These results reflect the growing rivalry in the weight-loss drug market and may influence future decisions on treatment options for obesity patients.